key: cord-0737866-v34516re
authors: Oley, Mendy Hatibie; Oley, Maximillian Christian; Kepel, Billy Johnson; Tjandra, Djony E.; Fredrik G. Langi, Fima Lanra; Herwen; Aling, Deanette Michelle R.; Joicetine Wagiu, Angelica Maurene; Faruk, Muhammad
title: ICAM-1 levels in patients with covid-19 with diabetic foot ulcers: A case-controlled, prospective, cohort study in southeast asia
date: 2021-02-10
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.02.017
sha: c8f4fa1663e321a6e0a075691484c58a334dd8fe
doc_id: 737866
cord_uid: v34516re

BACKGROUND: Viral infection can compound the severity of pre-existing inflammation caused by underlying diseases. For those with a chronic, immune-related condition such as diabetic foot ulcers (DFUs), the coronavirus disease (COVID-19) serves to exacerbate the inflammatory burden. Serum levels of intracellular adhesion molecule-1 (ICAM-1), a primary mediator of cell adhesion express in the inflammatory process, are often used to indicate the gravity of all inflammatory conditions. Therefore, the purpose of this study was to investigate serum ICAM-1 levels before and after debridement in patients with DFUs who were also diagnosed as COVID-19 positive compared with those who were COVID-19 negative. METHODS: 20 patients with DFUs were screened for COVID-19 and then divided into COVID-19 positive and negative groups according to the results. Before debridement, chest x-rays and blood analysis, including ICAM-1 serum levels, were performed in both groups. Only ICAM-1 serum levels were measured after debridement. RESULTS: Of the 20 patients included in this study, 55% were male (n = 11) and 45% were female (n = 9). The mean age was 52.9 ± 1.9 years. ICAM-1 levels in patients with DFU in the COVID-19-positive group were significantly higher than those in the COVID-19-negative group (median 317.2 vs 149.2, respectively; p < 0.001). Serum levels of ICAM-1 reduced significantly in patients with DFU in the COVID-19-positive group were significantly higher than those in the COVID-19-negative group after debridement (median 312.5 vs 130.3; p < 0.001). CONCLUSION: ICAM-1 serum levels represent an additional, initial screening marker for COVID-19.

Pre-existing inflammation caused by underlying diseases worsens in the presence of a viral infection. Coronavirus disease 2019 is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The common symptoms are fever, cough, dyspnea that can progress to pneumonia, acute respiratory distress syndrome, multiple organ failure, and death [1] [2] [3] . The first case of a 'pneumonia of unknown etiology' was reported on December 31, 2019, in Wuhan, Hubei Province, China by the World Health Organization (WHO) country office in China. The second case of coronavirus pneumonia was detected on January 7, 2020, and by March 11, 2020 , the WHO declared COVID-19 a global pandemic. As of September 30, 2020, global COVID-19 cases reached 33,249,563 with a mortality of 1,000,040 people. Indonesia reported 278,722 COVID-19 cases, with 10,473 deaths [4, 5] .

Diabetes is one of the known comorbidity factors for COVID-19 [6, 7] . The prevalence of diabetes mellitus increased from 108 million in 1980 to 422 million in 2014 according to the WHO. In Southeast Asia, the prevalence was 71.4 million in 2011 and this is predicted to increase to 120 million people in 2030 [8, 9] . Diabetes mellitus is a syndrome that includes metabolic and vascular aspects in which fasting, postprandial, or random blood glucose levels increase. It can be classified into two types, type 1 diabetes mellitus (insulin-dependent) and type 2 diabetes mellitus (non-insulin-dependent). Complications from type 2 diabetes mellitus are grouped into two categories, microvascular (e.g., diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy) and macrovascular (e.g., coronary vascular disease, peripheral vascular disease, brain vascular disease) [10] [11] [12] . Diabetic foot ulcers (DFUs) occur in more than 25% of patients with diabetes. It causes infection in 50% and amputation in 20% of patients. The number of lower extremity amputations is 10-20-fold higher in patients with diabetes compared with non-diabetics. Approximately 70-80% of all non-traumatic amputations are caused by diabetes.

Patients with DFUs, therefore, undergo debridement for infection control to prevent amputation [13, 14] .

Patients with DFUs are exposed to prolonged, low-grade inflammation and infection.

Triggered by inflammation, endothelial adhesion molecules such as ICAM-1 are produced in excessive amounts as a component of the immune response. Adding weight to the load, patients with DFUs who are also diagnosed with COVID-19 experience an acute inflammatory response on top of their pre-existing chronic inflammation. We hypothesize that ICAM-1 levels are elevated in these patients even after debridement. Therefore, this study aims to investigate the levels of ICAM-1 before and after debridement in patients with DFUs who are also diagnosed as COVID-19 positive compared with those who are COVID-19 negative. (STROCSS) guidelines [15] .

The population included in this study were patients with type 2 diabetes mellitus and Repeated measure analysis of variance (ANOVA) was used to determine the effect of time and the interaction between groups and time. All data were processed and analyzed using R group; however, this difference was not statistically significant (12.9 vs 16.3; p = 0.280). The median platelet counts for both groups were within normal limits. The NLR had a median over 3.13 with no significant difference observed between the two groups, although the value from the non-COVID-19 group was higher ( Table 1 ). The same was found for serum electrolyte levels, such as sodium, potassium, and chloride. There was no significant difference in the random blood sugar levels between the COVID-19 and non-COVID-19 groups (p = 0.323). Liver function parameters (SGPT and SGOT) were within the normal limits for both groups. Renal function tests (urea and serum creatinine) in the COVID-19 group appeared higher than the non-COVID-19 group (55.5 mg/dL and 1.9 mg/dL vs 33.5 mg/dL and 1.1 mg/dL). In contrast, serum albumin levels in the non-COVID-19 group indicated hypoalbuminemia (mean albumin serum 2.5 ± 0.7 g/dL) and were lower than the COVID-19 group (mean albumin serum 3.2 ± 0.5 g/dL; p = 0.027). Table 2 compares the relationship between serum ICAM-1 levels in the COVID-19 and non-COVID-19 groups before and after debridement and with other COVID-19 criteria, such as high NLR value, pneumonia, leukopenia or leucocytosis, and lymphocytopenia. Regardless of the time of examination (before or after debridement), serum ICAM-1 levels differed between patients in the swab-positive and negative groups. There were notable differences in ICAM-1 levels between the COVID-19 and non-COVID-19 groups at baseline and even after debridement (p < 0.001). However, the differences in ICAM-1 levels before and after debridement in each group were non-significant. Remarkable differences were also seen in the NLR values (p = 0.001) and leukocyte counts (p = 0.042). The results in Figure 1 mirror those presented in Table 2 , where ICAM-1 levels were significantly elevated in the COVID-19 group J o u r n a l P r e -p r o o f relative to the non-COVID-19 group, before and after debridement. The other criteria in Table 2 did not correlate significantly, except for the association between pneumonia and the results of the RT-PCR COVID-19 swab test. However, some patients with negative swab tests were also diagnosed with pneumonia during the treatment.

A novel finding from our study is that ICAM-1 levels were significantly elevated in patients with COVID-19 with DFUs compared with patients without COVID-19 (Table 2 & Figure 1 ). This suggests that ICAM-1 could be used as an additional biomarker of COVID-19 since inflammation plays a crucial role in the pathogenesis of the disease. Induced by inflammation, ICAM-1 facilitates leukocyte-endothelial binding and the migration of leukocytes across the endothelial barrier [21] . As such, elevated levels of ICAM-1 mark a pre-existing inflammation process. Moreover, a retrospective study in China of 39 patients with COVID-19

and 32 controls showed that the former had significantly increased levels of ICAM-1 and other endothelial adhesion molecules, which may contribute to coagulopathy [22] . COVID-19associated coagulopathy seems to happen due to excessive levels of von Willebrand factor, platelet activation, and hypercoagulability [23] . Therefore, an acute inflammatory process followed by a hypercoagulable state can contribute to the severity of COVID-19.

Diabetes is one of many comorbidity risk factors for COVID-19. The pathological mechanism underlying diabetes, including chronic inflammation and coagulopathy, encourages COVID-19 progression. Inflammatory biomarkers such as IL-6, C-reactive protein, serum ferritin, coagulation index, and D-dimer are increased in patients with diabetes compared with those without diabetes [24] . Other studies also found higher levels of serum ICAM-1 in patients with diabetes compared with controls [25] . In patients with diabetes, hyperglycemia causes both the innate and adaptive immune responses to become dysregulated; the resulting impairment contributes to the systemic tissue damage, respiratory and multiorgan failure, and inability to defend against invading pathogens characteristic of the disease. A harmful cytokine storm develops more readily when patients with diabetes are presented with an immune insult due to their preexistent, chronic low-grade hyper-inflammatory state. Moreover, particularly in cases with a high viral load, the capacity to mount an effective acute immune response against SARS-CoV-2 might be compromised in these patients, thereby rendering them more susceptible to the severe adverse effects associated with COVID-19 [24] . Moreover, hyperglycemia stimulates the J o u r n a l P r e -p r o o f production of coagulation factors such as von Willebrand factor, factor VII, factor VIII, factor IX, factor XII, the extrinsic pathway, and thrombin factor, which leads to excessive thrombus formation in the arteries, veins, and microvascular circulation [26] .

A complication associated with diabetes is DFUs caused by peripheral neuropathy, reduced peripheral blood flow, and peripheral artery disease [27] [28] [29] [30] . DFU management requires a multidisciplinary approach including blood glucose control, proper wound treatment, and eliminating risk factors that may hinder or delay the wound healing process. However, patients with COVID-19 are subjected to a severe systemic inflammatory response and hypercoagulability that further compromises the blood supply to the ulcer and adds additional burden to the ongoing infection by prolonging the inflammation, hence worsening the DFU outcome [27] .

Albumin is an essential protein in the wound healing process [31] . Low albumin levels are associated with inflammation and are often found in difficult-to-heal diabetes-associated wounds [32, 33] . Our findings support this theory as low albumin levels were found in both patient groups (Table 1 ). In addition, an observational study of patients with COVID-19 in Italy found that severe hypoalbuminemia is positively correlated with COVID-19 mortality (HR: 2.48, 95% CI:

1.44-4.26; p = 0.001) and is also associated with old age (R = −0.367; p < 0.001) [34] . In their historical prospective study, Akirov et al. also correlated hypoalbuminemia with mortality among hospitalized patients diagnosed with several comorbidities including malignancy, ischemic heart disease, and diabetes mellitus [35] . Unfortunately, the correlation between COVID-19 severity and low albumin levels were not analyzed in this study due to its small sample size and limited data collection period, which are the limitations of this study. Therefore, further research is needed to identify other parameters associated with COVID-19 that enable early diagnosis and, ideally, accurate prognosis.

The statistically significant increase in ICAM-1 serum levels among patients with COVID-19 compared with their non-COVID-19 counterparts supports the inclusion of this metric as a preliminary screening method for SARS-CoV-2 infection particularly for asymptomatic patients prior to surgery or other medical procedures to enable healthcare workers to take the proper precautions when providing care for these patients.

Not commissioned, externally peer-reviewed. 

WHO coronavirus disease (COVID-19)

Coronavirus disease 2019: What we know?

COVID-19): current status and future perspectives

WHO Declares COVID-19 a Pandemic

COVID-19 and diabetes cutaneous comorbidity

Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review

The Rising Burden of Diabetes and Hypertension in Southeast Asian and African Regions: Need for Effective Strategies for Prevention and Control in Primary Health Care Settings

Hyperbaric oxygen therapy in the healing process of foot ulcers in diabetic type 2 patients marked by interleukin 6, vascular endothelial growth factor, and PEDIS score: A randomized controlled trial study

Standards of Medical Care in Diabetes

Association, Diagnosis and classification of diabetes mellitus

Rutherford's Vasc. Surg

Diabetic foot disorders. A clinical practice guideline (2006 revision)

Guideline: Strengthening the reporting of cohort studies in surgery

Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance

Comparison of SARS-CoV-2 detection from combined nasopharyngeal/oropharyngeal swab samples by a laboratory-developed real-time RT-PCR test and the Roche SARS-CoV-2 assay on a cobas 8800 instrument

The implementation of a rapid sample preparation method for the detection of SARS-CoV-2 in a diagnostic laboratory in South Africa

Association of superoxide dismutase enzyme with staging and grade of differentiation colorectal cancer: A cross-sectional study

Role of CAPE in reducing oxidative stress in animal models with traumatic brain injury

ICAM-1: role in inflammation and in the regulation of vascular permeability

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a singlecentre, cross-sectional study

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Intercellular adhesion molecule-1 in diabetic patients with and without microalbuminuria

Incidence of deep vein thrombosis in patients with diabetic foot ulcers

Managing diabetic foot in times of COVID-19: time to put the best 'foot' forward

Diabetic neuropathy

Understanding diabetic foot

Effect of serum albumin in wound healing and its related complications in surgical patients

Hypoalbuminemia: Pathogenesis and Clinical Significance

A prospective cohort study of hypoalbuminemia as risk factor of wound healing in diabetic foot: a study from tertiary hospital in south India

Is Albumin Predictor of Mortality in COVID-19?

Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients

FIGURE LEGEND Figure 1. The relationship between serum ICAM-1 level and RT-PCR COVID-19 swab test results based on time of examination, pre-(1) and post-(2) ulcer debridement. P-value for repeated-measure ANOVA for swab test

We would like to thank all doctors and patients at the Faculty of Medicine, Sam Ratulangi University and Prof. Dr. R. D. Kandou Hospital Manado, Indonesia, who contributed to this study.

• In patients with diabetes, hyperglycemia causes both the innate and adaptive immune responses to become dysregulated.• ICAM-1 facilitates leukocyte-endothelial binding and the migration of leukocytes across the endothelial barrier.• ICAM-1 levels in patients with DFU in the COVID-19-positive group were significantly higher than those in the COVID-19-negative group.• ICAM-1 serum levels represent an additional, initial screening marker for COVID-19.J o u r n a l P r e -p r o o f

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.The authors declare that they have no conflict of interests.

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.No funding or sponsorship.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.All procedure for human experiment has been approved by Ethics Commission of Kandou Hospital Manado, Number: 039/EC-KEPK/V/2020. J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The patients have given their written informed consent on admission to use their prospective data base and files for research work.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. J o u r n a l P r e -p r o o f

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.This study has been registered with the Research Registry no. 6341.https://www.researchregistry.com/register-now#home/registrationdetails/5fcce2e1748734001c96ba4c/

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Mendy Hatibie Oley J o u r n a l P r e -p r o o f